Adlai Nortye (ANL) Competitors $1.57 +0.05 (+3.26%) Closing price 07/3/2025 11:51 AM EasternExtended Trading$1.56 0.00 (-0.06%) As of 07/3/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. SLRN, VOR, NBTX, BTMD, TVGN, CGC, PRQR, CRDF, EPRX, and TVRDShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Acelyrin (SLRN), Vor Biopharma (VOR), Nanobiotix (NBTX), biote (BTMD), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Eupraxia Pharmaceuticals (EPRX), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Acelyrin Vor Biopharma Nanobiotix biote Semper Paratus Acquisition Canopy Growth ProQR Therapeutics Cardiff Oncology Eupraxia Pharmaceuticals Tvardi Therapeutics Acelyrin (NASDAQ:SLRN) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment. Which has more volatility and risk, SLRN or ANL? Acelyrin has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500. Does the media prefer SLRN or ANL? In the previous week, Acelyrin's average media sentiment score of 0.00 equaled Adlai Nortye'saverage media sentiment score. Company Overall Sentiment Acelyrin Neutral Adlai Nortye Neutral Do analysts prefer SLRN or ANL? Acelyrin currently has a consensus price target of $9.60, suggesting a potential upside of 322.91%. Adlai Nortye has a consensus price target of $9.00, suggesting a potential upside of 474.71%. Given Adlai Nortye's higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation & earnings, SLRN or ANL? Adlai Nortye has higher revenue and earnings than Acelyrin. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcelyrinN/AN/A-$381.64M-$2.69-0.84Adlai Nortye$5M11.56-$51.87MN/AN/A Is SLRN or ANL more profitable? Adlai Nortye's return on equity of 0.00% beat Acelyrin's return on equity.Company Net Margins Return on Equity Return on Assets AcelyrinN/A -44.12% -39.02% Adlai Nortye N/A N/A N/A Do institutionals and insiders hold more shares of SLRN or ANL? 87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAcelyrin and Adlai Nortye tied by winning 5 of the 10 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.35M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E RatioN/A21.5627.6120.24Price / Sales11.56278.93417.30118.22Price / CashN/A42.7336.8958.10Price / Book2.277.518.035.67Net Income-$51.87M-$55.14M$3.18B$249.21M7 Day Performance-4.22%4.61%2.93%3.28%1 Month Performance-9.53%4.72%3.75%5.55%1 Year Performance-52.55%5.92%35.20%21.09% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.8255 of 5 stars$1.57+3.3%$9.00+474.7%-57.0%$55.35M$5M0.00127SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135VORVor BiopharmaN/A$1.83+13.0%N/AN/A$228.68MN/A-1.21140Gap UpHigh Trading VolumeNBTXNanobiotix1.6909 of 5 stars$4.82+1.9%$8.00+65.9%-7.1%$227.21M$39.18M0.00100Positive NewsGap UpBTMDbiote3.0999 of 5 stars$4.13+2.7%$8.00+93.7%-43.1%$225.95M$197.19M6.77194News CoverageTVGNSemper Paratus Acquisition3.988 of 5 stars$1.22-2.8%$10.00+723.0%+81.5%$223.43MN/A0.003CGCCanopy Growth2.844 of 5 stars$1.21-1.2%$2.00+66.0%-80.0%$221.56M$225.65M-0.303,150Positive NewsPRQRProQR Therapeutics2.1302 of 5 stars$2.01-1.3%$8.00+297.2%+30.7%$212.00M$20.46M-5.76180News CoverageCRDFCardiff Oncology1.6907 of 5 stars$3.19+1.1%$9.88+210.0%+62.5%$211.90M$680K-3.4620EPRXEupraxia Pharmaceuticals2.4715 of 5 stars$5.89+2.3%$11.00+86.8%+118.6%$211.80MN/A-7.7529Positive NewsGap UpTVRDTvardi TherapeuticsN/A$22.61-3.1%$71.50+216.2%N/A$211.63M$7.14M0.0080 Related Companies and Tools Related Companies Acelyrin Alternatives Vor Biopharma Alternatives Nanobiotix Alternatives biote Alternatives Semper Paratus Acquisition Alternatives Canopy Growth Alternatives ProQR Therapeutics Alternatives Cardiff Oncology Alternatives Eupraxia Pharmaceuticals Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts